IMNM supply chain intelligence for Immunome, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AYALA-PHARMACEUTICALS-INC | AYALA-PHARMACEUTICALS-INC | 80% | In connection with the closing of the Ayala Purchase Agreement in March 2024, the Company assumed a license agreement, the BMS License Agreement, with Bristol-Myers Squibb Company, or BMS, pursuant t… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and d… |
| BMY | Bristol-Myers Squibb Company | 72% | riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and development expenses Intangible assets acquired in an asset acquisition or license… |
| BMYMP | Bristol-Myers Squibb Co | 72% | riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and development expenses Intangible assets acquired in an asset acquisition or license… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: riod. No further collaboration revenue will be recognized under the Collaboration Agreement. In-process research and… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| JNJ | Johnson & Johnson | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| LLY | Eli Lilly and Company | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: -party contract manufacturers, or t… |
| MYGN | Myriad Genetics, Inc. | 72% | -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addit… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: third parties with whom we work) … |
| NVSEF | Novartis AG | 72% | third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement actions; private litigation (including cla… |
| ORANY | ORANY | 72% | ernment regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: ernment regulation that may arise… |
| SNYNF | Sanofi | 72% | -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. In addit… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, imp… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from ZNTL g… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial competition, which may result in others discov… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ABBV | AbbVie Inc. | 85% | Reciprocal relationship from ABBV graph: Reciprocal relationship from IMNM graph: generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have gene… |
| ABBVIE-GLOBAL-ENTERPRISES-LTD | ABBVIE-GLOBAL-ENTERPRISES-LTD | 85% | generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have generated our revenue through a Collaboration and Option Agreement, or the Collaborati… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from BMY graph: Reciprocal relationship from IMNM graph: er 31, 2025 and 2024 , respectively. … |
| BMY | Bristol-Myers Squibb Company | 72% | er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s common stock at an aggregate fair value of $ million on the acquisition date. The f… |
| BMYMP | Bristol-Myers Squibb Co | 72% | er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s common stock at an aggregate fair value of $ million on the acquisition date. The f… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from IMNM graph: er 31, 2025 and 2024 , respectively. million in cash, and (ii) the issuance of unregistered shares of the Company’s … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in ot… |
| JNJ | Johnson & Johnson | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| LLY | Eli Lilly and Company | 72% | m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in clinical trials may later drop out due to… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from LLY grap… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or acci… |
| MYGN | Myriad Genetics, Inc. | 72% | ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, discl… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from IMNM graph: third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulator… |
| NVSEF | Novartis AG | 72% | third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations; government enforcement actions; private litigation (including cla… |
| ORANY | ORANY | 72% | ernment regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional state and federal health care reform … |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from IMNM graph: ernment regulation that may arise from future legislation or administrative or executive action, either in the Unite… |
| SNYNF | Sanofi | 72% | ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, discl… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from SNYN… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on study design. ● We face substantial competition, which may result in others discov… |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ZNTL graph: Reciprocal relationship from IMNM graph: be delayed or otherwise adversely affected. ● We may experience delays in completion of our clinical trials based on … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IMNM-DEBT-10242 | Warrants outstanding: 10 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| IMNM-DEBT | Debt stack $3.7M | 90% | Market cache reports total debt of $3.7M. |
| IMNM-DEBT-10243 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IMNM-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 200 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 |